Literature DB >> 31527267

Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity.

Jan Hülsdünker1,2,3, Oliver S Thomas1,2,3, Eileen Haring1,3, Susanne Unger4, Nicolás Gonzalo Núñez4, Sonia Tugues4, Zhan Gao5, Sandra Duquesne1, Colette Cywes-Bentley6, Ozlem Oyardi6,7, Susanne Kirschnek8, Annette Schmitt-Graeff9, Oliver Pabst10, Christian Koenecke11, Justus Duyster1, Petya Apostolova1, Martin J Blaser5, Burkhard Becher4, Gerald B Pier6, Georg Häcker8, Robert Zeiser12,13.   

Abstract

Microbial invasion into the intestinal mucosa after allogeneic hematopoietic cell transplantation (allo-HCT) triggers neutrophil activation and requires antibiotic interventions to prevent sepsis. However, antibiotics lead to a loss of microbiota diversity, which is connected to a higher incidence of acute graft-versus-host disease (aGVHD). Antimicrobial therapies that eliminate invading bacteria and reduce neutrophil-mediated damage without reducing the diversity of the microbiota are therefore highly desirable. A potential solution would be the use of antimicrobial antibodies that target invading pathogens, ultimately leading to their elimination by innate immune cells. In a mouse model of aGVHD, we investigated the potency of active and passive immunization against the conserved microbial surface polysaccharide poly-N-acetylglucosamine (PNAG) that is expressed on numerous pathogens. Treatment with monoclonal or polyclonal antibodies to PNAG (anti-PNAG) or vaccination against PNAG reduced aGVHD-related mortality. Anti-PNAG treatment did not change the intestinal microbial diversity as determined by 16S ribosomal DNA sequencing. Anti-PNAG treatment reduced myeloperoxidase activation and proliferation of neutrophil granulocytes (neutrophils) in the ileum of mice developing GVHD. In vitro, anti-PNAG treatment showed high antimicrobial activity. The functional role of neutrophils was confirmed by using neutrophil-deficient LysM cre Mcl1 fl/fl mice that had no survival advantage under anti-PNAG treatment. In summary, the control of invading bacteria by anti-PNAG treatment could be a novel approach to reduce the uncontrolled neutrophil activation that promotes early GVHD and opens a new avenue to interfere with aGVHD without affecting commensal intestinal microbial diversity.

Entities:  

Keywords:  GVHD; microbiome; neutrophil granulocytes

Year:  2019        PMID: 31527267      PMCID: PMC6789638          DOI: 10.1073/pnas.1908549116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages.

Authors:  Ivan Dzhagalov; Ashley St John; You-Wen He
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

2.  The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

Authors:  Ying Taur; Robert R Jenq; Miguel-Angel Perales; Eric R Littmann; Sejal Morjaria; Lilan Ling; Daniel No; Asia Gobourne; Agnes Viale; Parastoo B Dahi; Doris M Ponce; Juliet N Barker; Sergio Giralt; Marcel van den Brink; Eric G Pamer
Journal:  Blood       Date:  2014-06-17       Impact factor: 22.113

3.  α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice.

Authors:  Hidetaka Uryu; Daigo Hashimoto; Koji Kato; Eiko Hayase; Satomi Matsuoka; Reiki Ogasawara; Shuichiro Takahashi; Yoshinobu Maeda; Hiromi Iwasaki; Toshihiro Miyamoto; Shinobu Saijo; Yoichiro Iwakura; Geoffrey R Hill; Koichi Akashi; Takanori Teshima
Journal:  Blood       Date:  2015-03-04       Impact factor: 22.113

Review 4.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

5.  Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection.

Authors:  Andrea Kropec; Tomas Maira-Litran; Kimberly K Jefferson; Martha Grout; Sarah E Cramton; Friedrich Götz; Donald A Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.

Authors:  Casie Kelly-Quintos; Andrea Kropec; Stacy Briggs; Claudia L Ordonez; Donald A Goldmann; Gerald B Pier
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

7.  The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation.

Authors:  H Olkinuora; E von Willebrand; J M Kantele; O Vainio; K Talvensaari; U Saarinen-Pihkala; S Siitonen; K Vettenranta
Journal:  Scand J Immunol       Date:  2011-06       Impact factor: 3.487

8.  MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease.

Authors:  Markus M Heimesaat; Axel Nogai; Stefan Bereswill; Rita Plickert; André Fischer; Christoph Loddenkemper; Ulrich Steinhoff; Sandrine Tchaptchet; Eckhard Thiel; Marina A Freudenberg; Ulf B Göbel; Lutz Uharek
Journal:  Gut       Date:  2010-08       Impact factor: 23.059

9.  Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.

Authors:  Melha Mellata; Natalie M Mitchell; Florian Schödel; Roy Curtiss; Gerald B Pier
Journal:  Vaccine       Date:  2015-12-18       Impact factor: 3.641

10.  Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated.

Authors:  D D Poutsiaka; D Munson; L L Price; G W Chan; D R Snydman
Journal:  Bone Marrow Transplant       Date:  2010-05-17       Impact factor: 5.483

View more
  9 in total

Review 1.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.

Authors:  Robert Zeiser; Gérard Socié
Journal:  Blood Adv       Date:  2020-08-11

Review 3.  Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.

Authors:  Gérard Socié; Leslie S Kean; Robert Zeiser; Bruce R Blazar
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 19.456

Review 4.  The microbiome-the revealing of a long time unbeknownst factor for outcome in murine models of graft-versus-host disease.

Authors:  Reena Kumari; Senthilnathan Palaniyandi; Gerhard Carl Hildebrandt
Journal:  Bone Marrow Transplant       Date:  2021-05-29       Impact factor: 5.174

5.  Microbiome: an emerging new frontier in graft‑versus‑host disease.

Authors:  Reena Kumari; Senthilnathan Palaniyandi; Ethan Strattan; Gerhard C Hildebrandt
Journal:  Inflamm Res       Date:  2020-11-13       Impact factor: 4.575

Review 6.  Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561

Review 7.  Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Hemasphere       Date:  2021-06-01

Review 8.  Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation.

Authors:  Cristina Tecchio; Marco Antonio Cassatella
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

Review 9.  Acute Graft-Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System.

Authors:  Janaki Manoja Vinnakota; Robert Zeiser
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.